|
|
|
|
|
|
|
|
|
|
|
|
|
09.03.26 - 19:00
|
UK inflation likely to rise because of Middle East war, says Rachel Reeves (The Guardian)
|
|
|
British chancellor says she will take steps to help families with cost of living as oil prices surge Middle East crisis – live updatesBritain is likely to be hit by rising inflation because of the US war with Iran, the UK chancellor, Rachel Reeves, has said, as she suggested that a “rapid de-escalation” would be the best protection against a jump in energy prices.Both the chancellor and the prime minister, Keir Starmer, suggested the government would be prepared to intervene to protect UK households against major cost-of-living shocks as oil prices surged past $100 (£75) a barrel for the first time since 2022. Continue reading......
|
|
|
|
|
|
|
|
|
09.03.26 - 18:24
|
Will Lloyds shares rise 25% or 39% by this time next year? (Fool)
|
|
|
Lloyds shares are expected to rebound after sinking to fresh multi-month peaks. Royston Wild considers the outlook for the FTSE 100 bank.
The post Will Lloyds shares rise 25% or 39% by this time next year? appeared first on The Motley Fool UK....
|
|
|
|
|
|
|
09.03.26 - 18:18
|
CCL, RCL, NCLH Stocks Slammed as Oil Prices Surge and Geopolitical Tensions Roil Cruise Sector (24/7 Wall St.)
|
|
|
Shares of Carnival (NYSE:CCL) are getting hit in midday trading on Monday, sitting at $24.72, down nearly 3% on the session with an intraday low of $23.47. This caps a brutal stretch: -15% over the past week and -26.78% over the past month. The entire cruise sector is under pressure, but CCL is taking the ... CCL, RCL, NCLH Stocks Slammed as Oil Prices Surge and Geopolitical Tensions Roil Cruise Sector
The post CCL, RCL, NCLH Stocks Slammed as Oil Prices Surge and Geopolitical Tensions Roil Cruise Sector appeared first on 24/7 Wall St.....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
09.03.26 - 18:01
|
MaaT Pharma to Present Four Abstracts at the 52nd European Bone Marrow Transplantation Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on acute GvHD Management (Business Wire)
|
|
|
Oral presentation during Presidential Plenary Session to feature the final results of the ARES pivotal Phase 3 trial evaluating MaaT013 in acute Graft‑versus‑Host Disease (aGvHD) with gastrointestinal involvement
Poster presentations for:
CHRONOS, a multicenter retrospective cohort study describing real-world outcomes in third-line acute gastrointestinal GvHD not treated with microbiotherapy
PHOEBUS, a Phase 2b trial, potentially pivotal, evaluating MaaT033 seeking to improve survival after allogeneic hematopoietic transplantation (HCT)
THRASSA, a multicenter, open‑label paediatric/adolescent study evaluating MaaT013 in patients with ruxolitinib‑refractory or ruxolitinib‑intolerant gastrointestinal aGvHD
Clinigen, MaaT Pharma's strategic commercial partner for MaaT013's Early Access Program and commercialization in Europe pending European Medicines Agency (EMA) approval, will host an Industry Symposium on advancing care for steroid-refractory gastrointestinal aGvHD
LYON, France--(BUSINESS WIRE...
|
|
Alle News zu Großbritannien 10265.203 -0.54% (FTSE 100 Kurs)
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
